Allogene Therapeutics Dividende

Zukünftiges Wachstum Kriterienprüfungen 0/6

Wichtige Informationen

n/a

Dividendenausschüttung

n/a

Ausschüttungsquote

Durchschnittlicher Branchenertrag	2.8%
Nächster Dividendenzahlungstermin	n/a
Ex-Dividendendatum	n/a
Dividende pro Aktie	n/a
Gewinn pro Aktie	-US$1.40
Erwartete Dividendenrendite in 3 Jahren	0%

Aktuelle Dividendenentwicklung

Keine Aktualisierungen

Recent updates

Allogene: Two End Of 2024 Data Readouts With Improved Allogeneic CAR-T Products

Jun 12

We Discuss Why Allogene Therapeutics, Inc.'s (NASDAQ:ALLO) CEO Compensation May Be Closely Reviewed

May 30

Allogene Therapeutics: 2024 Platform Vision Sings Mid-Term Upside

Apr 01

We Think Allogene Therapeutics (NASDAQ:ALLO) Needs To Drive Business Growth Carefully

Mar 01

We Think Allogene Therapeutics (NASDAQ:ALLO) Needs To Drive Business Growth Carefully

Jun 09

We're Hopeful That Allogene Therapeutics (NASDAQ:ALLO) Will Use Its Cash Wisely

Feb 22

Allogene Therapeutics (NASDAQ:ALLO) Is In A Good Position To Deliver On Growth Plans

Oct 27

Allogene begins phase 2 allogeneic CAR T trial for large B-cell lymphoma candidate

Oct 06

An Intrinsic Calculation For Allogene Therapeutics, Inc. (NASDAQ:ALLO) Suggests It's 23% Undervalued

Sep 22

Allogene: Possible First Pivotal Study With Allogeneic CAR-T ALLO-501A

Sep 13

Allogene Therapeutics GAAP EPS of -$0.52 beats by $0.08, revenue of $0.09M beats by $0.07M

Aug 09

Companies Like Allogene Therapeutics (NASDAQ:ALLO) Are In A Position To Invest In Growth

Jul 14

Stabilität und Wachstum des Zahlungsverkehrs

Rufe Dividendendaten ab

Stabile Dividende: Es liegen keine ausreichenden Daten vor, um festzustellen, ob die Dividende je Aktie von ALLO in der Vergangenheit stabil war.

Wachsende Dividende: Unzureichende Daten, um festzustellen, ob die Dividendenzahlungen von ALLO gestiegen sind.

Dividendenrendite im Vergleich zum Markt

Allogene Therapeutics Dividendenrendite im Vergleich zum Markt

Wie sieht die Dividendenrendite von ALLO im Vergleich zum Markt aus?
Segment	Dividendenrendite
Unternehmen (ALLO)	n/a
Untere 25 % des Marktes (US)	1.6%
Markt Top 25 % (US)	4.8%
Branchendurchschnitt (Biotechs)	2.8%
Analystenprognose in 3 Jahren (ALLO)	0%

Bemerkenswerte Dividende: Es ist nicht möglich, die Dividendenrendite von ALLO im Vergleich zu den unteren 25 % der Dividendenzahler zu bewerten, da das Unternehmen keine aktuellen Ausschüttungen gemeldet hat.

Gewinnausschüttung an die Aktionäre

Abdeckung der Erträge: Unzureichende Daten zur Berechnung der Ausschüttungsquote von ALLO, um festzustellen, ob die Dividendenzahlungen durch die Gewinne gedeckt sind.

Barausschüttung an die Aktionäre

Cashflow-Deckung: Es ist nicht möglich, die Nachhaltigkeit der Dividende zu berechnen, da ALLO keine Ausschüttungen gemeldet hat.

Allogene Therapeutics Dividende

Zukünftiges Wachstum Kriterienprüfungen 0/6

Wichtige Informationen

Aktuelle Dividendenentwicklung

Recent updates

Allogene Therapeutics, Inc. Announces Executive Changes

Allogene: Two End Of 2024 Data Readouts With Improved Allogeneic CAR-T Products

We Discuss Why Allogene Therapeutics, Inc.'s (NASDAQ:ALLO) CEO Compensation May Be Closely Reviewed

Consensus revenue estimates increase by 2,115%

Allogene Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $110.000002 million.

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Allogene Therapeutics, Inc. to Report Q1, 2024 Results on May 13, 2024

Allogene Therapeutics Receives Grant from the California Institute for Regenerative Medicine to Advance Development of an Allogeneic CAR T in Renal Cell Carcinoma

Allogene Therapeutics Receives Grant from the California Institute for Regenerative Medicine to Advance Development of an Allogeneic CAR T in Renal Cell Carcinoma

Allogene Therapeutics: 2024 Platform Vision Sings Mid-Term Upside

Consensus revenue estimates decrease by 43%, EPS upgraded

Co-Founder notifies of intention to sell stock

Full year 2023 earnings: EPS and revenues miss analyst expectations

Allogene Therapeutics, Inc. to Report Q4, 2023 Results on Mar 14, 2024

We Think Allogene Therapeutics (NASDAQ:ALLO) Needs To Drive Business Growth Carefully

Insider notifies of intention to sell stock

Allogene Therapeutics Announces 2024 Platform Vision to Redefine the Future of Car T Led by ALPHA3

Consensus revenue estimates increase by 10%

Allogene Therapeutics, Inc. Presents Comprehensive Safety Data of Proprietary Lymphodepletion Agent ALLO-647

Price target decreased by 8.5% to US$13.13

Consensus revenue estimates increase by 23%

Price target decreased by 14% to US$14.36

Allogene Therapeutics, Inc. Presents Preclinical Data on Next Generation Cloak and Dagger Technologies At the Society for Immunotherapy of Cancer Annual Meeting

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Allogene Therapeutics, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Allogene Therapeutics, Inc. Appoints Geoffrey Parker as Executive Vice President

Consensus revenue estimates increase by 34%

New minor risk - Shareholder dilution

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Allogene Therapeutics, Inc. to Report Q2, 2023 Results on Aug 02, 2023

New minor risk - Share price stability

Allogene Therapeutics Provides Additional ALLO-501/501A Phase 1 Data in an Oral Presentation at the International Conference on Malignant Lymphoma (ICML) Lugano

Allogene Therapeutics, Inc. Announces Resignation of Eric Schmidt from Principal Financial Officer and Principal Accounting Officer, Effective from August 2, 2023

We Think Allogene Therapeutics (NASDAQ:ALLO) Needs To Drive Business Growth Carefully

Allogene Therapeutics, Inc. Presents Long-Term Follow Up Data from Phase 1 ALPHA/ALPHA2 Trials of ALLO-501/501A in Patients with Relapsed/Refractory Large B-Cell Lymphoma at American Society of Clinical Oncology Annual Meeting in Chicago, Illinois

Consensus revenue estimates increase by 96%

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus revenue estimates decrease by 99%, EPS upgraded

Full year 2022 earnings: EPS and revenues exceed analyst expectations

We're Hopeful That Allogene Therapeutics (NASDAQ:ALLO) Will Use Its Cash Wisely

Allogene Therapeutics, Inc. Presents Data on Dagger, a Next Generation AlloCAR T Platform Technology

Allogene Therapeutics Publishes Preclinical Data in Clinical Cancer Research Supporting DLL3 as a Potential AlloCAR T™ Target for Small Cell Lung Cancer

Allogene Therapeutics Announces Publication in Nature Medicine of Data from its Phase 1 UNIVERSAL Study of ALLO-715 for the Treatment of Relapsed/Refractory Multiple Myeloma

Price target decreased by 7.4% to US$22.00

Price target decreased to US$23.00

Allogene Appoints Zachary J. Roberts as Executive Vice President of Research & Development

Price target decreased to US$24.06

Allogene Therapeutics R&D Showcase Features Hematologic and Solid Tumor Advances Across its AlloCAR T™ Platform

Price target decreased to US$25.00

Insufficient new directors

Consensus revenue estimates increase by 26%

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Allogene Therapeutics (NASDAQ:ALLO) Is In A Good Position To Deliver On Growth Plans

Allogene Therapeutics, Inc. to Report Q3, 2022 Results on Nov 02, 2022

Now 23% undervalued after recent price drop

Insider notifies of intention to sell stock

Allogene Therapeutics Inc. Launches CAR T Together, Focuses on Accelerating Development and Clinical Trial Recruitment for “Off-The-Shelf” Allogeneic Cell Therapy Investigational Products

Allogene Therapeutics, Inc. Initiates Industry’s First Allogeneic CAR T Phase 2 Trial

Allogene begins phase 2 allogeneic CAR T trial for large B-cell lymphoma candidate

An Intrinsic Calculation For Allogene Therapeutics, Inc. (NASDAQ:ALLO) Suggests It's 23% Undervalued

Now 24% undervalued after recent price drop

Allogene: Possible First Pivotal Study With Allogeneic CAR-T ALLO-501A

Board Member recently sold US$251k worth of stock

Consensus revenue estimates increase by 37%

Price target increased to US$27.88

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Allogene Therapeutics GAAP EPS of -$0.52 beats by $0.08, revenue of $0.09M beats by $0.07M

Allogene Therapeutics, Inc. to Report Q2, 2022 Results on Aug 09, 2022

Companies Like Allogene Therapeutics (NASDAQ:ALLO) Are In A Position To Invest In Growth

Allogene Therapeutics, Inc. Appoints Scientific Pioneer Stephen Mayo to its Board of Directors

Allogene Therapeutics, Inc.(NasdaqGS:ALLO) dropped from Russell 2000 Growth Index

Board Member recently sold US$118k worth of stock

Allogene Therapeutics: Multibagger Potential, But Terribly Risky

Allogene Therapeutics, Inc. Announces the FDA Granted Regenerative Medicine Advanced Therapy (RMAT) Designation to ALLO-501A for Large B Cell Lymphoma

Insider recently sold US$85k worth of stock